Alternatively, email editorial-team (at). Have feedback on this article? Concerned about the content? Get in touch with us directly. Simply Wall St has no position in any stocks mentioned. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. We aim to bring you long-term focused analysis driven by fundamental data. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. This article by Simply Wall St is general in nature. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
#NASDAQ ICAD FREE#
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). It may be that the market is pretty optimistic about iCAD if you look to the bottom line. Shareholders should be pretty happy with that, although interested investors might want to examine the financial data more closely to see if the gains are really justified. In comparison, the share price rise of 52% per year over the last three years is pretty impressive. That's not a very high growth rate considering it doesn't make profits. In the last 3 years iCAD saw its revenue grow at 7.3% per year. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Given that iCAD didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. The thing to consider is whether the underlying business is doing well enough to support the current price.Īlthough iCAD has shed US$33m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns. After a run like that some may not be surprised to see prices moderate. In three years the stock price has launched 249% higher: a great result. But that doesn't undermine the rather lovely longer-term return, if you measure over the last three years. ( NASDAQ:ICAD) shareholders might understandably be very concerned that the share price has dropped 41% in the last quarter. Register for your free account today at, Inc. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. ET of the following day.ĭata provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Start Time: 16:30 End Time: 17:28 iCAD, Inc.
![nasdaq icad nasdaq icad](https://logo.stocklight.com/NASDAQ/ICAD.png)
![nasdaq icad nasdaq icad](https://s3.tradingview.com/s/sHaaBbXQ_mid.png)
will report pre-market and after hours trades. Investors who anticipate trading during these times are strongly advised to use limit orders. Stock prices may also move more quickly in this environment. Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. ET) and the After Hours Market (4:00-8:00 p.m. Investors may trade in the Pre-Market (4:00-9:30 a.m.
![nasdaq icad nasdaq icad](https://i1.rgstatic.net/publication/241212929_sMAX_A_Multimodal_Toolkit_for_Stock_Market_Data_Sonification/links/00463528c8ea2badd0000000/largepreview.png)